COEP
HealthcareCoeptis Therapeutics Holdings, Inc.
$14.79
+$0.15 (+1.02%)
Jan 5, 2026
Price History (1Y)
Analysis
Coeptis Therapeutics Holdings, Inc. is a biotechnology company within the healthcare sector. With a market capitalization of $78.98 million and annual revenue of $500,996, it operates at a relatively small scale with just 5 employees. The company's financial health is marked by significant losses, as evidenced by net income of -$12,389,202 and EBITDA of -$12,081,319 in the trailing twelve months. This has resulted in negative profitability metrics, including an operating margin of -1043.2% and a profit margin of 0.0%. Returns on equity (-171.9%) and assets (-71.4%) are also negative. The balance sheet shows $5.33 million in cash and $279,865 in debt, with a debt-to-equity ratio of 2.56. The company's valuation metrics indicate a relatively low price-to-book ratio of 7.36 and a high price-to-sales ratio of 157.65. The forward P/E ratio is -87.00, while the EV/EBITDA ratio stands at -6.10. Dividend-related metrics are not applicable due to zero payout ratio and no dividend yield.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $78.98M
- P/E Ratio
- N/A
- 52-Week High
- $21.41
- 52-Week Low
- $3.80
- Avg Volume
- 67.37K
- Beta
- -0.49
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 5